Skip to Main Content

A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors

Conditions

Phase I

Phase I

What is the purpose of this trial?

This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.

  • Trial with
    Cybrexa Therapeutics, Inc.
  • Start Date
    06/13/2022
  • End Date
    01/01/2024

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/14/2022
  • Study HIC
    #2000030687